The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Globe Investor

News Sources

Take control of your investments with the latest investing news and analysis

Press release from GlobeNewswire (a Nasdaq OMX company)

TearLab Corporation Reports 2012 Financial Results

Wednesday, March 20, 2013

TearLab Corporation Reports 2012 Financial Results04:30 EDT Wednesday, March 20, 2013SAN DIEGO, March 20, 2013 (GLOBE NEWSWIRE) -- TearLab Corporation (Nasdaq:TEAR) (TSX:TLB) ("TearLab" or the "Company") today reported its consolidated financial results for the quarter and the year ended December 31, 2012. All dollar amounts are expressed in U.S. currency and results are reported in accordance with United States generally accepted accounting principles. For the three months ended December 31, 2012, TearLab's net revenues were $1.6 million, up more than three-fold from $499,000 for the same period in 2011 and an increase of 33% sequentially from $1.2 million in the previous quarter. A total of 232 orders for TearLab systems were booked in the fourth quarter. Of those, 201 were through the Company's access programs, 12 were direct purchases and 19 were purchased outside of the U.S. The Company's net loss for the three months ended December 31, 2012 was approximately $3.7 million, or $0.13 per share. This included approximately $0.3 million in non-cash expense related to the revaluation of warrants issued in June 2011. In last year's fourth quarter, the net loss was $3.5 million, or $0.17 per share. This included approximately $0.7 million in non-cash expense related to the revaluation of warrants issued in June 2011. For the year ended December 31, 2012, TearLab's net revenues were approximately $4.0 million as compared to $2.1 million in 2011. The Company's net loss for the year ended December 31, 2012 was approximately $19.3 million, or $0.76 per share. This included approximately $7.3 million in non-cash expense related to the revaluation of warrants issued in June 2011. For the year ended December 31, 2011, the loss was $8.8 million, or $0.50 per share. This included approximately $0.7 million in non-cash expense related to the revaluation of warrants issued in June 2011. 2012 cash used in operating activities was approximately $8.8 million. As of December 31, 2012, TearLab had $15.4 million in cash and cash equivalents. "As demonstrated by our system order volumes for the fourth quarter, we had a very strong showing at the American Academy of Ophthalmology ("AAO") annual meeting in November," commented Elias Vamvakas, TearLab's Chief Executive Officer. "To help put that in perspective, 45% of total 2012 system orders came in the fourth quarter alone. While that sales performance was not fully reflected in our Q4-2012 financial results due to the lag between contract signing and product shipment, it is clear that we are starting to build a substantial recurring revenue base for the future." Mr. Vamvakas continued, "Now, despite the absence of large events like AAO, growing doctor interest in our technology and the significant role that it can play in the objective diagnoses and management of Dry Eye Disease has continued to drive positive momentum in the first quarter of 2013. Moving forward, we plan on continuing to execute our marketing strategy and to build our sales organization in order to help the groundbreaking TearLab® Osmolarity test grow to its full potential."Conference Call and Webcast Information TearLab will hold a conference call to discuss these results today, March 20, at 8:30am Eastern Time at 877-303-1593. The call will also be broadcast live and archived on TearLab's website at www.tearlab.com under the "webcasts" link in the Investor Relations section. For those wishing to listen to a recording of the call via telephone, a replay will be made available as soon as possible after the conclusion of the live call and will remain posted for a period of seven days. To listen to the recording, simply telephone (Toll free) 855-859-2056 or (Toll) 404-537-3406 and enter reservation #14510627 when prompted.About TearLab Corporation TearLab Corporation (www.tearlab.com) develops and markets lab-on-a-chip technologies that enable eye care practitioners to improve standard of care by objectively and quantitatively testing for disease markers in tears at the point-of-care. The TearLab Osmolarity Test, for diagnosing Dry Eye Disease, is the first assay developed for the award-winning TearLab Osmolarity System. Headquartered in San Diego, CA, TearLab Corporation's common shares trade on the NASDAQ Capital Market under the symbol 'TEAR' and on the Toronto Stock Exchange under the symbol 'TLB'.Forward-Looking Statements This press release may contain forward-looking statements. These statements relate to future events and are subject to risks, uncertainties and assumptions about TearLab. Examples of forward-looking statements in this press release include statements regarding our future recurring revenue expectations and our plans for executing our marketing strategy and building a salesforce, the future potential of the TearLab® Osmolarity System and the related impact on our sales. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. Many factors may cause our actual results to differ materially from any forward-looking statement, including the factors detailed in our filings with the Securities and Exchange Commission and Canadian securities regulatory authorities, including but not limited to our annual and quarterly reports on Forms 10-K and 10-Q. We do not undertake to update any forward-looking statements.TearLab Corp.    CONSOLIDATED STATEMENTS OF OPERATIONS (expressed in U.S. dollars except number of shares) ($ 000's)    Three months ended December 31Year ended December 31  2012 2011 2012 2011 Revenue $ 1,610  $ 499$ 3,960  $ 2,124Cost of goods sold 930 409 2,295  1,626Gross profit 680 90 1,665  498Operating expenses        Amortization of intangible assets 304 304 1,215  1,215 General and administrative 1,140 1,100 4,770  3,842 Clinical, regulatory and research & development 618 542 2,241  1,304 Sales and marketing 1,942 865  5,471  2,195 Total operating expenses 4,004 2,811 13,697  8,556Loss from operations (3,324)  (2,721) (12,032)  (8,058)Other income (expenses)(328) (751) (7,280)  (751)Net loss(3,652) (3,472) (19,312)  (8,809)Weighted average number of shares outstanding – basic and diluted28,607,209 20,414,993 25,490,186   17,744,736Net loss per common share – basic and diluted $ (0.13)  $ (0.17) $ (0.76)  $ (0.50)      TearLab Corp.     CONSOLIDATED BALANCE SHEETS (expressed in U.S. dollars) ( $ 000's)       December 31, 2012 December 31, 2011      ASSETS    Current assets     Cash and cash equivalents$ 15,437 $ 2,807 Accounts receivable, net889 321 Inventory, net1,863 898 Prepaid expenses387 190 Other current assets60 35Total current assets18,636 4,251      Fixed assets, net630 199 Patents and trademarks, net136 164 Intangible assets, net4,709 5,924 Other non-current assets28 —Total assets$ 24,139 $ 10,538      LIABILITIES AND STOCKHOLDERS' EQUITY   Current liabilities    Accounts payable$ 1,067 $ 218 Accrued liabilities1,989 1,843 Obligations under warrants6,239 2,957Total current liabilities9,295 5,018        Stockholders' equity    Capital stock    Preferred Stock, $0.001 par value, 10,000,000 authorized none outstanding— — Common stock, $0.001 par value, 65,000,000 authorized, 28,741,653 issued and outstanding at December 31, 2012 and 40,000,000 authorized, 20,414,993 issued and outstanding at December 31, 201129 20 Additional paid-in capital421,662 393,035 Accumulated deficit(406,847) (387,535)Total stockholders' equity14,844 5,520Total liabilities and stockholders' equity$ 24,139 $ 10,538CONTACT: Investors: Stephen Kilmer (905) 906-6908 skilmer@tearlab.com Media: Leonard Zehr Managing Director Kilmer Lucas Inc. (905) 486-1158 len@kilmerlucas.com